Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gastroenteropancreatic Neuroendocrine Neoplasm”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT06784752
What this trial is testing

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

Who this might be right for
Somatostatin Receptor Positive (SSTR+)Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Novartis Pharmaceuticals 240
Testing effectiveness (Phase 2)UnknownNCT04427787
What this trial is testing

A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET

Who this might be right for
Metastatic Well Differentiated Neuroendocrine NeoplasmNeuroendocrine Tumors
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 69
Early research (Phase 1)Active Not RecruitingNCT04609592
What this trial is testing

Study of PRRT in Metastatic, WHO Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Stanford University 10
Testing effectiveness (Phase 2)Study completedNCT03079440
What this trial is testing

TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine TumorsNeuroendocrine CarcinomaTemozolomide+1 more
Asan Medical Center 31
Testing effectiveness (Phase 2)Study completedNCT02955069
What this trial is testing

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Who this might be right for
Well-differentiated Non-functional NET of Thoracic OriginWell-differentiated Non-functional NET of Gastrointestinal OriginWell-differentiated Non-functional NET of Pancreatic Origin+1 more
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Enrolling By InvitationNCT05385861
What this trial is testing

Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET

Who this might be right for
GEP-NET
National Health Research Institutes, Taiwan 52
Not applicableStudy completedNCT04946305
What this trial is testing

A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea

Who this might be right for
Somatostatin Receptor-positive GEP-NET
Novartis Pharmaceuticals 89
Early research (Phase 1)Active Not RecruitingNCT04234568
What this trial is testing

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

Who this might be right for
Metastatic Digestive System Neuroendocrine NeoplasmMetastatic Neuroendocrine Tumor
National Cancer Institute (NCI) 31
Not applicableStudy completedNCT04649580
What this trial is testing

United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting

Who this might be right for
Neuroendocrine Tumours (NET)
Ipsen 80
Early research (Phase 1)Looking for participantsNCT07006727
What this trial is testing

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

Who this might be right for
Small Cell Lung CarcinomaLarge Cell Neuroendocrine Carcinoma of the LungNeuroendocrine Prostate Cancer+8 more
Novartis Pharmaceuticals 116
Post-approval studies (Phase 4)Study completedNCT04524442
What this trial is testing

Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Advanced Accelerator Applications 42
Large-scale testing (Phase 3)Looking for participantsNCT05884255
What this trial is testing

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Who this might be right for
Advanced Gastroenteropancreatic Neuroendocrine Tumor
Jiangsu HengRui Medicine Co., Ltd. 220
Not applicableStudy completedNCT00745381
What this trial is testing

A Collection of Clinical and Epidemiologic Data Combined With Tissue and Blood From Patients With a Diagnosis of Neuroendocrine Tumors

Who this might be right for
Gastric CancerPancreatic Cancer
Memorial Sloan Kettering Cancer Center 238
Testing effectiveness (Phase 2)WithdrawnNCT04915144
What this trial is testing

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

Who this might be right for
Neuroendocrine TumorsCarcinoid TumorPulmonary Carcinoid Tumor+4 more
British Columbia Cancer Agency
Post-approval studies (Phase 4)Looking for participantsNCT05701241
What this trial is testing

Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
University Hospital, Antwerp 270
Testing effectiveness (Phase 2)Looking for participantsNCT05048901
What this trial is testing

Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors,Gastroenteropancreatic
National Health Research Institutes, Taiwan 49
Testing effectiveness (Phase 2)Ended earlyNCT03670030
What this trial is testing

TestABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System

Who this might be right for
Neuroendocrine Tumors
Robert Ramirez 5
Not applicableStudy completedNCT06853457
What this trial is testing

A Transfer Learning Radiomics Model for Predicting Response to Initial Transarterial Embolization in Patients with Gastroenteropancreatic Neuroendocrine Tumor Liver Metastases

Who this might be right for
Neuroendocrine Tumors, NET
First Affiliated Hospital, Sun Yat-Sen University 257
Not applicableUnknownNCT05334290
What this trial is testing

Financial Toxicity and Patient-Reported Outcomes in GEP-NEN During Treatment

Who this might be right for
Neuroendocrine Tumors
Massimo Falconi 400
Very early researchUnknownNCT05359146
What this trial is testing

Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)

Who this might be right for
Neuroendocrine Neoplasia's (NENs)Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
University Hospital, Basel, Switzerland 16
Next Page
116